Oral birch pollen immunotherapy with apples: Results of a phase II clinical pilot study.

Bettina NotheggerNorbert ReiderClaudia E CovaciuValentina CovaLinda AhammerReiner EidelpesJana UnterhauserStefan PlatzgummerElisabeth RaffeinerMartin TollingerThomas LetschkaKlaus Eisendle

Published in: Immunity, inflammation and disease (2021)

After 8 months of therapy, patients showed increased tolerance to apples (p < .001) and a decreased skin reactivity to apples. Oral allergy syndrome to other birch prFA than apple also decreased (p < .05). Moreover, daily rhinoconjunctivitis CSMS declined by 34% (p < .001), as did conjunctival reactivity to birch pollen extract by 27% (p < .01), while specific IgG4 to Mal d 1 and Bet v 1 increased (p < .01).

Keyphrases

phase ii
end stage renal disease
clinical trial
chronic kidney disease
newly diagnosed
ejection fraction
open label
peritoneal dialysis
physical activity
prognostic factors
oxidative stress
patient reported outcomes
soft tissue
wound healing
phase iii
double blind
placebo controlled